

Results presentation Q1 2026

Andreas Reisse, CEO | Reinhard Mayer, CFO

The fiscal year 2026 runs from October 2025 to September 2026.

© SCHOTT Pharma

Disclaimer

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.

These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (<https://www.schott-pharma.com/investor-relations>).

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.



Strategy and Business Update

Andreas Reisse, CEO



Positive start to financial year 2026



EUR **240**_m

Revenue

(+4.8 % at constant currencies)



EUR **65**_m

EBITDA

(margin of 27.1 %)




57 %

HVS revenue share

(+2 percentage points year-over-year)



Expansion of strong-margin HVS drives profitable growth



HVS' strategic importance

Strong-margin HVS drive growth and margin expansion.

Strategy focuses on addressing pharma trends with innovation.

Continuous increase of HVS revenue share reflects success.



Meeting growing demand



Innovation



Enabling ADC therapies

SCHOTT Pharma's new EVERIC® Iyo & amber vials offer a solution for the safe lyophilization and storage of light sensitive antibody drug conjugates (ADCs).



Trusted partner



Pre-validated system

New SCHOTT Pharma's TOPPAC® polymer cartridges compatible with SHL Medical large-volume autoinjectors.



Expansion



HVS expansion

Additional manufacturing capacity, particularly in Switzerland and Hungary.



Financial Update


Reinhard Mayer, CFO



Strong top-line performance with growth driven by high-value solutions

Revenue¹

EURm



¹ Segment split excluding consolidation effects, cc = at constant currencies



Key developments

First quarter revenue grew slightly above expectations, mainly driven by strong HVS performance

Segment revenue in Drug Containment Solutions (DCS) grew by 9.4% at constant currencies, fueled by continued strong demand for sterile cartridges and specialty vials.


Drug Delivery Systems (DDS) revenues proved resilient, at the level of the prior-year quarter, with strong glass syringe performance offsetting dampened polymer demand.



EBITDA improved

EBITDA¹ and margin

EURm



¹ Segment split excluding consolidation effects



Key developments

Strong EBITDA performance as a result of an overall favorable shift towards HVS.

DCS EBITDA surged by 18.9%, due to volume and beneficial product-mix effects, resulting in a strong improvement of the EBITDA margin to 24.3% (+2.4pp).

DDS EBITDA declined in line with expectations, resulting in a margin of 31.6% (-2.5pp) and impacted by product-mix effects, lower utilization in polymer and ramp-up costs for new glass syringe capacities.



Further down the P&L...

EURm	Q1 2026	Q1 2025	Δ yoy
EBIT	44	40	+9.0%
Financial result	-2	-3	-47.7%
EBT	42	37	+14.2%
Income tax expense	-9	-7	+24.5%
Profit for the period	33	30	+11.8%
EPS (EUR)	0.22	0.20	+11.8%



Key developments

EBIT +9% driven by volume growth.

The financial result improved mainly due to lower interest expenses within the cash-pool financing structure.

Income taxes grew to EUR 9m representing an effective tax rate of 20.8%.


Overall, net income increased 12% yoy to EUR 33m and the earnings per share (EPS) amounted to EUR 0.22.



Investments into future growth continued at prior-year levels, phasing effect impacts cash flow

Free cash flow

EURm



Key developments


Reduced operating cash flow mainly impacted by a deferred payment by a major customer.

Capital expenditure of EUR 23.4m slightly above prior year's level, primarily focused on expansion of HVS capacities.

¹Op. CF = Cash flow from operating activities; ²Inv. CF = Cash flow from ongoing investing activities



FY 2026 guidance confirmed



Revenue growth¹

2% – 5%



EBITDA margin

~27%

Additional information

CAPEX² of EUR 140 – 160m | HVS revenue share on prior year's level

¹At constant currencies; ²Capex excluding leasing



Thank you for your attention



Next financial events

May 13, 2026:
H1/Q2 2026 results

Aug 12, 2026:
9M/Q3 2026 results

Dec 10, 2026:
FY/Q4 2026 results



Next conference participations

Mar 3, 2026:
Morgan Stanley
European Healthcare
Conference
London

Mar 4, 2026:
UBS
European Healthcare
Conference
London

Mar 9, 2026:
Bank of America
Injectable Drug
Package call series
Virtual

Mar 24, 2026:
BNP
European Healthcare
Conference
London